Novel therapeutic strategies for advanced ovarian cancer by using induced pluripotent stem cell‐derived myelomonocytic cells producing interferon beta

Autor: Hidetaka Katabuchi, Kiyomi Takaishi, Yoshihiro Komohara, Takashi Ohba, Yuko Imamura, Yasuharu Nishimura, Junko Tsuboki, Dashdemberel Narantuya, Miwa Haruta, Gandolgor Tsend‐Ayush, Hironori Tashiro, Satoru Senju
Jazyk: angličtina
Rok vydání: 2018
Předmět:
0301 basic medicine
Cancer Research
medicine.medical_treatment
Induced Pluripotent Stem Cells
macrophage
Mice
SCID
iPS cell
Monocytes
03 medical and health sciences
Peritoneal cavity
Mice
0302 clinical medicine
Basic and Clinical Immunology
interferon‐β
Cell Line
Tumor
Ascites
medicine
Animals
Humans
Induced pluripotent stem cell
Peritoneal Neoplasms
Ovarian Neoplasms
Chemotherapy
business.industry
Cancer
peritoneal dissemination
General Medicine
Original Articles
Interferon-beta
medicine.disease
Xenograft Model Antitumor Assays
Coculture Techniques
030104 developmental biology
medicine.anatomical_structure
ovarian cancer
Treatment Outcome
Oncology
Tumor progression
030220 oncology & carcinogenesis
Cancer cell
Cancer research
Original Article
Female
medicine.symptom
Ovarian cancer
business
Zdroj: Cancer Science
ISSN: 1349-7006
1347-9032
Popis: Although first-line chemotherapy has a high rate of complete responses in ovarian cancer patients, the vast majority of patients present with recurrent disease that has become refractory to conventional chemotherapy. Peritoneal dissemination and malignant ascites are the hallmarks of recurrent or advanced ovarian cancer and severely reduce quality of life. Development of therapeutic measures to treat such patients is eagerly anticipated. Macrophage infiltration is observed in various types of cancer including epithelial ovarian cancer. In addition, macrophages are involved in the formation of spheroids in the malignant ascites of ovarian cancer and promote cancer growth. iPS-ML, macrophage-like myelomonocytic cells generated from human induced pluripotent stem (iPS) cells, made close contacts with ovarian cancer cells in vitro. We hypothesized that, if we inoculate iPS-ML-producing IFN-β (iPS-ML/IFN-β) into the peritoneal cavity of patients with ovarian cancer, IFN-β produced by the iPS-ML/IFN-β would efficiently act on the cancer cells to suppress cancer growth. To evaluate this hypothesis, we injected iPS-ML/IFN-β into SCID mice bearing peritoneally disseminated human ovarian cancer cells, SKOV3. Immunohistochemical analysis of the intraperitoneal tumors detected iPS-ML/IFN-β infiltrating into the cancer tissues. Therapy with iPS-ML/IFN-β significantly suppressed tumor progression. In addition, dramatic reduction of cancer-related ascites was observed. Collectively, it is suggested that iPS-ML/IFN-β therapy offers a new approach for the treatment of patients with advanced ovarian cancer.
Databáze: OpenAIRE
Externí odkaz: